CriticalClass III antiarrhythmic, selective IKr blocker×Fourth-generation fluoroquinolone
Updated · Methodology
Mechanism
Dofetilide is a class III antiarrhythmic. It blocks the rapid component of the delayed rectifier potassium current (IKr), and QT prolongation depends directly on its plasma concentration (dofetilide label, US Food and Drug Administration, FDA). Moxifloxacin itself prolongs the QT interval in some patients. The Spanish moxifloxacin summary of product characteristics (SmPC) states that an additive effect on QT with other QT-prolonging drugs cannot be excluded. This may increase the risk of ventricular arrhythmias, including torsade de pointes (moxifloxacin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). QT prolongation may increase with higher plasma concentrations of moxifloxacin and with fast intravenous infusion (AEMPS; moxifloxacin FDA label). The documents describe no pharmacokinetic interaction for this pair. A metabolic interaction of moxifloxacin through cytochrome P450 enzymes is unlikely (AEMPS), and dofetilide does not inhibit these enzymes (dofetilide FDA label).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). The Medication Guide of the US dofetilide label lists the warning signs of a dangerous arrhythmia: feeling faint, dizziness and a fast heartbeat. It warns that torsade de pointes can lead to death (dofetilide label, US Food and Drug Administration, FDA). In people with supraventricular arrhythmias who took dofetilide, torsade de pointes occurred in 0.8%, mostly within the first three days of treatment. Low potassium or magnesium increases the risk (FDA). The adverse reactions of moxifloxacin include ventricular tachyarrhythmias, syncope, torsade de pointes and cardiac arrest (moxifloxacin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination is contraindicated. The Spanish moxifloxacin summaries of product characteristics (SmPCs) contraindicate moxifloxacin with class III antiarrhythmics and name dofetilide. Their contraindications section also states that moxifloxacin must not be given together with other drugs that prolong the QT interval (moxifloxacin SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The US moxifloxacin label says to avoid moxifloxacin in patients receiving class IA or class III antiarrhythmics (moxifloxacin label, US Food and Drug Administration, FDA). The US dofetilide label does not recommend dofetilide with other QT-prolonging drugs and names certain fluoroquinolones among them (dofetilide FDA label). Dofetilide is not in the Spanish medicines register CIMA. Moxifloxacin is also contraindicated in documented congenital or acquired QT prolongation, electrolyte disturbances (especially uncorrected low potassium), clinically relevant bradycardia, clinically relevant heart failure with reduced left ventricular ejection fraction and a history of symptomatic arrhythmias (AEMPS). If dofetilide is stopped so that a potentially interacting drug can be given, wait at least two days before starting that drug (FDA). No document states how long to wait after stopping moxifloxacin before starting dofetilide. The mean elimination half-life of moxifloxacin is about 12 hours (AEMPS). Start or restart dofetilide only in a facility that can calculate creatinine clearance, provide continuous electrocardiogram (ECG) monitoring and perform cardiac resuscitation for at least three days. Dofetilide is contraindicated if the QT or heart-rate-corrected QT interval (QTc) is above 440 ms (500 ms with ventricular conduction abnormalities). Keep potassium in the normal range before and during treatment (FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Moxifloxacin tablets (Chartwell RX) – prescribing information (2026)– FDA label, Chartwell RX, DailyMed setid 656f582c-ecba-4ec8-9420-9562114d889b, version 1, 08/2026, sections 5.6 (QT Prolongation) and 7.5 (Drugs that Prolong QT)
- AEMPS: Ficha técnica: Moxifloxacino (nº registro 74573), sección 4.5 (2026)– AEMPS, CIMA, nº registro 74573, revisión 03/2026, sección 4.5
- FDA: TIKOSYN (dofetilide) capsules prescribing information (2026)– FDA, DailyMed setid 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (Pfizer), revisión 04/2026 (versión 30), Boxed Warning, Contraindications, Warnings (Ventricular Arrhythmia, Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents), Precautions (Drug-Drug Interactions), Dosage and Administration
- AEMPS: Ficha técnica: Moxifloxacino, Actira 400 mg/250 ml solución para perfusión (nº registro 83222), sección 4.3 (2026)– AEMPS, CIMA, nº registro 83222 (Actira 400 mg/250 ml solución para perfusión, Bayer Hispania), revisión 02/2026, secciones 4.3, 4.4, 4.5 y 4.8
- AEMPS: Ficha técnica: Moxifloxacino, Actira 400 mg/250 ml solución para perfusión (nº registro 83222), sección 4.5 (2026)– AEMPS, CIMA, nº registro 83222 (Actira 400 mg/250 ml solución para perfusión, Bayer Hispania), revisión 02/2026, sección 4.5